Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy in the Management of Post-Stroke Spasticity in Romania
Conclusions: This therapy should be taken into account when considering rehabilitation options because it is highly cost-effective at < EURO 1,000/QALY gained, a very low WTP (Willingness To Pay) threshold. INCO proved to be a disruptive innovation because it is a new and more effective treatment, and, in the end, much higher in quality of life for patients with post-stroke upper limb spasticity.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Disability | Drugs & Pharmacology | Men | Rehabilitation | Romania Health | Stroke | Study